BRAF and neoplasm: We applied whole-exome sequencing (WES) and/or targeted gene sequencing on baseline tumor and/or plasma cell-free DNA (cfDNA) samples from a large cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, as well as from a control cohort of patients with mCRCBRAF-V600E receiving standard chemotherapies and antiangiogenic agents (and not exposed to anti-BRAF), and integrated these data with clinical correlates of response and survival.